Estrogen, Progesterone, and Mood: What Every Woman Should Know

Hormones and mood are deeply connected. Estrogen and progesterone do not only regulate reproductive health. They also directly control mood, cognition, and brain function. Research from Frontiers in Pharmacology (2025) confirms this clearly. These hormones influence serotonin, dopamine, and GABA, the key neurotransmitter systems that regulate emotional wellbeing. Yet most women experiencing anxiety or depression during a hormonal transition never receive a hormonal evaluation. Instead, they receive a general psychiatric diagnosis.

This article explains the estrogen progesterone mood connection in plain terms. First, it covers how each hormone affects the brain. Then, it identifies the life stages where hormonal mood changes are most common. Finally, it describes what a proper evaluation looks like and what questions to bring to a licensed provider. For a broader overview of women’s hormonal health, the article on Sexual Health at VitalBalance is a useful starting point.

How Estrogen Affects Mood: The Neuroscience

The Serotonin Connection

Estrogen is widely regarded as a neuroprotective hormone, meaning it actively supports brain function rather than simply reflecting it. Its effects on mood operate through multiple neurotransmitter systems simultaneously, which explains why estrogen decline or fluctuation produces such a wide range of psychological symptoms that do not fit neatly into standard psychiatric categories.

The serotonin connection is the most established. Estrogen increases serotonin synthesis by upregulating tryptophan hydroxylase, the enzyme that produces serotonin from its amino acid precursor. It simultaneously increases the density and sensitivity of serotonin receptors and reduces the activity of the serotonin transporter (the reuptake mechanism that SSRIs target). The practical consequence of this triple action is that adequate estrogen amplifies serotonergic tone in the brain. When estrogen falls or fluctuates dramatically, serotonin availability is reduced through all three of these pathways at once, creating a state of serotonergic dysregulation that can present as depression, irritability, and emotional instability.

Dopamine, GABA, and Beyond

Estrogen also modulates dopamine, norepinephrine, and GABA systems. Dopaminergic effects contribute to motivation, reward sensitivity, and focus. Noradrenergic effects influence energy, alertness, and stress reactivity. GABA effects affect the inhibitory tone of the nervous system, the biological mechanism that keeps anxiety and emotional reactivity in check. This breadth of neurochemical involvement is why estrogen fluctuation can produce a symptom picture that overlaps with depression, anxiety, ADHD-like attention difficulties, and emotional dysregulation simultaneously.

How Progesterone Affects Mood: The GABA Connection

Progesterone’s mood effects operate through a different and in some ways more direct pathway than estrogen’s. Progesterone is metabolized in the brain to a neurosteroid called allopregnanolone (ALLO), which is a potent positive allosteric modulator of GABA-A receptors. In plain terms, allopregnanolone activates the brain’s primary inhibitory signaling system, producing an anxiolytic, sedating, and mood-stabilizing effect that functions similarly to benzodiazepines but through natural endogenous pathways.

The significance of this progesterone-allopregnanolone-GABA pathway for estrogen progesterone mood disorders cannot be overstated. When progesterone is adequate and its metabolic conversion to allopregnanolone is functioning normally, women have a natural biological buffer against anxiety, nervous system overactivation, and sleep disruption. When progesterone declines, this buffer is reduced or removed.

Progesterone begins declining before estrogen does in perimenopause, as ovulation becomes less consistent and the luteal phase shortens. This means many women in their late 30s and early 40s experience the mood consequences of progesterone decline, specifically increased anxiety, heightened emotional reactivity, sleep disruption, and a reduced ability to tolerate stress, before any change in their menstrual cycle pattern would suggest a hormonal cause. The scientific evidence linking allopregnanolone fluctuations to reproductive mood disorders, including PMDD and postpartum depression, has been strong enough to support FDA approval of brexanolone (Zulresso), a synthetic allopregnanolone analog, for postpartum depression in 2019. This represented the first pharmaceutical approval directly targeting the allopregnanolone-GABA pathway for mood.

The Estrogen Progesterone Mood Pattern Across Life Stages

The estrogen progesterone mood relationship does not follow a simple linear trajectory. It produces different mood challenges at different hormonal life stages, each with its own clinical presentation.

Perimenopausal Depression: Why It Gets Missed

Perimenopausal depression deserves particular attention because it is among the most consistently misidentified mood disorders in clinical practice. Community-based epidemiologic studies document a 1.5 to 3 times greater risk of first-onset depression during the perimenopausal transition compared to the premenopausal period, even in women with no prior history of mood disorders. A global analysis published in 2024 found that between 40 and 50% of perimenopausal women report mood and mental health challenges. And yet the vast majority receive antidepressants that do not address the hormonal root cause, rather than an evaluation of the estrogen progesterone mood picture.

The clinical presentation of perimenopausal mood disruption is distinctive. It tends to be characterized by anxiety, irritability, anger, and emotional lability more than by the persistent low mood that defines classic major depression. Brain fog, poor concentration, and reduced stress tolerance are common features. Mood changes are often cyclical in early perimenopause, tracking with hormonal fluctuations, before becoming more persistent as estrogen eventually declines. Hot flashes, when present, compound the picture by disrupting sleep, which independently worsens mood regulation.

A 2019 publication in Menopause authored by the NAMS-commissioned expert panel on perimenopausal depression concluded that the perimenopausal transition is a time of heightened vulnerability to mood symptoms and that estrogen therapy should be considered as a first-line treatment for perimenopausal depression, particularly in women within 10 years of menopause onset who do not have contraindications. This represents a significant shift from the older default of antidepressants as the first intervention.

What the Evidence Shows About Treating Estrogen Progesterone Mood Symptoms

The treatment evidence for hormonally-driven mood disorders has become substantially clearer over the past decade, as researchers have distinguished between mood symptoms rooted in hormonal fluctuation and those with primary psychiatric etiology.

Estrogen Therapy for Perimenopausal Depression

For perimenopausal depression specifically, the evidence for estrogen therapy is strong. The KEEPS-Cognitive and Affective Study (KEEPS-Cog) examined women within 3 years of menopause and found that oral conjugated equine estrogen and transdermal estradiol both improved mood outcomes compared to placebo. Multiple smaller controlled trials support this finding. The effect appears most pronounced in women who are close to the onset of the menopausal transition, consistent with the broader window of opportunity concept discussed in the our blog.

Progesterone Type Matters for Mood

For progesterone specifically, oral micronized progesterone, the body-identical form, is generally preferred over synthetic progestins when addressing mood symptoms. This distinction is clinically significant. Oral micronized progesterone is metabolized to allopregnanolone and produces the anxiolytic and sleep-supportive GABA-A receptor effects described above. Synthetic progestins, particularly medroxyprogesterone acetate, are not metabolized to allopregnanolone and do not produce the same mood-supportive effects. Some synthetic progestins may even worsen mood in susceptible individuals.

For PMDD, the most severe form of luteal-phase mood disruption, the FDA-approved treatment options include continuous or luteal-phase SSRIs and the oral contraceptive containing drospirenone. The FDA approval of brexanolone for postpartum depression in 2019 validated the allopregnanolone-GABA pathway as a therapeutic target. A related compound, zuranolone, received FDA approval in 2023 for both postpartum depression and major depressive disorder, with a specific mechanism targeting GABA-A receptor modulation.

Where Testosterone Fits in the Estrogen Progesterone Mood Picture

The estrogen progesterone mood conversation is incomplete without acknowledging testosterone’s contribution. Women’s testosterone levels decline from the late 30s through menopause, and testosterone contributes to energy, motivation, mood, and cognitive function through androgenic pathways that are distinct from estrogenic and progestogenic effects. A 2024 pilot study published in Archives of Women’s Mental Health found that transdermal testosterone therapy improved mood and cognitive symptoms in peri- and postmenopausal women, suggesting that the androgen contribution to mood is clinically relevant even when estrogen and progesterone are being addressed.

For women with documented low testosterone alongside mood and energy changes, this is worth raising in a comprehensive hormone evaluation. For more on how testosterone fits into women’s hormone optimization, the article on Sexual Health page covers adrenal androgen decline and its mood-related consequences. For women also interested in sexual health aspects of hormonal decline, the Sexual Health page covers the FDA-approved peptide option for hypoactive sexual desire disorder.

What a Thorough Evaluation Looks Like

The evaluation for hormonally-driven mood symptoms should be integrated rather than fragmented. Seeing a gynecologist for hot flashes, a psychiatrist for mood, and an endocrinologist for thyroid, without these providers communicating, produces incomplete care. A provider who specializes in women’s hormone health will assess all of the following in a single evaluation: estradiol (best measured on day 2 or 3 of a cycle if still cycling), progesterone (day 21 for luteal phase assessment), FSH and LH for menopause staging, total and free testosterone and SHBG, a complete thyroid panel, DHEA-S, a metabolic panel, and a full symptom and psychiatric history that distinguishes hormonally-sensitive mood changes from primary mood disorders.

Questions worth bringing to that conversation include: Has my hormonal status been formally evaluated? Has my testosterone been tested, not just estrogen and FSH? If hormone therapy is recommended, what formulation and delivery route is being proposed and why? Would progesterone type and route affect my mood specifically? Is there a follow-up plan to assess mood response to any hormonal intervention? For the full picture on HRT options and evidence, the Peptide Therapy page covers how these approaches can work in combination.

Frequently Asked Questions

Can hormones really cause depression and anxiety, or is it just stress?

Both can be true simultaneously, but they are not the same thing and they do not respond to the same treatments. The research is clear that estrogen and progesterone directly regulate neurotransmitter systems involved in mood, including serotonin, GABA, dopamine, and norepinephrine. When these hormones fluctuate or decline, the neurochemical environment changes in ways that produce depression, anxiety, and emotional reactivity through biological pathways, not through psychological interpretation of circumstances. Community-based epidemiologic studies document a 1.5 to 3 times greater risk of first-onset depression during the perimenopausal transition even in women with no prior history of mood disorders and no major life stressors. This does not mean stress is irrelevant. It means that for many women in hormonal transition, mood symptoms have a biological driver that requires hormonal investigation, not just psychological support or antidepressant medication.

Why does progesterone affect mood when it is usually discussed as a reproductive hormone?

Progesterone has effects well beyond reproductive function. Its primary metabolite in the brain, allopregnanolone, is a potent positive modulator of GABA-A receptors, the brain’s main inhibitory signaling system. Allopregnanolone’s GABA-A activity produces anxiolytic, sedating, and mood-stabilizing effects through the same receptor that benzodiazepines target, but through a natural endogenous pathway. When progesterone declines, allopregnanolone levels fall, and the inhibitory buffering of the nervous system is reduced. This produces increased anxiety, heightened stress reactivity, poorer sleep architecture, and greater emotional volatility. The strength of this evidence led to FDA approval of brexanolone, a synthetic allopregnanolone analog, for postpartum depression in 2019 and zuranolone for postpartum and major depression in 2023.

What is the difference between PMS and PMDD in terms of hormonal mechanisms?

Both PMS and PMDD are caused by sensitivity to the drop in estrogen and progesterone (and therefore allopregnanolone) in the luteal phase, the 7 to 10 days before menstruation. The difference is in severity and functional impact. PMS produces mild to moderate mood changes, bloating, and physical discomfort that do not significantly impair daily function. PMDD produces severe mood symptoms, including marked irritability, depression, anxiety, and emotional lability, that cause significant impairment in work, relationships, or social function. The key distinguishing feature is that symptoms resolve within a few days of menstruation onset in both conditions, confirming the hormonal rather than purely psychological mechanism. Women with PMDD appear to have a heightened neurological sensitivity to normal hormonal fluctuations rather than abnormally large hormonal changes, a distinction that matters for treatment selection.

Does hormone therapy actually improve mood, or does it just help with hot flashes?

The evidence for mood-specific benefits of hormone therapy is meaningful, particularly in women who are close to the onset of menopause. The KEEPS-Cognitive and Affective Study found that both oral and transdermal estrogen formulations improved mood outcomes in women within 3 years of menopause compared to placebo. A 2019 NAMS expert panel concluded that estrogen therapy should be considered as a first-line intervention for perimenopausal depression in women within 10 years of menopause onset without contraindications. The mood benefits are not simply a secondary consequence of better sleep from reduced hot flashes. They appear to be a direct effect of estrogen on serotonergic and other neurotransmitter pathways. The type of progestogen also matters for mood: oral micronized progesterone, which is metabolized to allopregnanolone, tends to support mood and sleep, while some synthetic progestins may worsen mood in susceptible individuals.

My doctor says my hormones are normal but I feel terrible. What should I do?

Reference ranges define population distributions, not individual optimal levels. A single FSH test is insufficient to evaluate the hormonal picture during perimenopause because FSH fluctuates significantly from cycle to cycle. A more complete evaluation includes estradiol (ideally measured on day 2 or 3 of the cycle), progesterone (measured on day 21 for luteal phase assessment), total and free testosterone, SHBG, LH, FSH, and a complete thyroid panel because thyroid dysfunction produces an overlapping symptom set. A woman who tests normal on a limited hormonal screen may still have meaningful hormonal contributors to her mood symptoms. A provider who specializes in women’s hormone health will use a more comprehensive evaluation framework than is typical in general practice. You can also ask specifically: was my testosterone tested? Was my estradiol measured on the right day of my cycle? Was progesterone included?

How do I know if my mood changes are hormonal or a primary psychiatric disorder?

Several features suggest a hormonal contribution rather than a primary psychiatric disorder. Mood changes that track with the menstrual cycle, particularly worsening in the luteal phase and improving after menstruation, suggest hormonal sensitivity. Mood changes that emerged at a hormonal transition point, such as postpartum, after stopping contraception, or in the early 40s without obvious life-circumstance triggers, suggest a hormonal driver. The presence of other perimenopausal symptoms alongside mood changes, including hot flashes, sleep disruption, night sweats, or changes in libido, increases the likelihood of a hormonal component. Primary psychiatric disorders, by contrast, tend to not follow hormonal cycles, do not resolve predictably at specific phases, and may have a clearer relationship to psychological or environmental triggers. In practice, many women have a combination of both, and a thorough evaluation addresses each rather than defaulting to one explanation.

Is there a link between hormones and anxiety specifically, not just depression?

Yes, and the anxiety connection may be even stronger than the depression connection in perimenopause. A global analysis found that between 40 and 50% of perimenopausal women report anxiety disorders, and global projections suggest a 40.67% increase in anxiety disorder burden among perimenopausal women by 2035. The mechanism is direct: progesterone decline reduces allopregnanolone, which reduces GABAergic inhibitory tone in the brain, increasing nervous system reactivity and anxiety sensitivity. Estrogen fluctuations further destabilize neurotransmitter systems. The result is that many perimenopausal women describe a qualitative change in their anxiety, feeling more reactive, less able to tolerate uncertainty, more easily overwhelmed, that does not respond well to standard anxiety management strategies because the biological buffering system has been reduced. Hormonal evaluation and appropriate intervention can address this at the root rather than only at the symptom level.

Can peptide therapy help with hormonally-driven mood symptoms?

Peptide therapy does not directly target the estrogen progesterone mood pathways. GH-stimulating peptides like Sermorelin and Tesamorelin act on the growth hormone axis, which is a separate endocrine system. However, there is indirect relevance. Improved sleep quality, which GH peptides can support through their effect on sleep architecture, has a meaningful downstream effect on mood stability. GH axis decline also contributes to energy and motivation changes that overlap with the mood picture of hormonal decline. For women exploring a comprehensive approach to hormonal wellness where both hormone therapy and peptide therapy may be relevant, a licensed provider can explain how peptide and hormone approaches may complement each other in your specific protocol.

References

1. Kulkarni J, et al. Using estrogen and progesterone to treat premenstrual dysphoric disorder, postnatal depression and menopausal depression. Front Pharmacol. 2025;16:1528544. frontiersin.org
2. Bendis PC, et al. The impact of estradiol on serotonin, glutamate, and dopamine systems. Front Neurosci. 2024;18. PubMed PMID 38586193
3. Maki PM, et al. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. Menopause. 2019;26(5):481-497. PubMed PMID 30855370
4. Gordon JL, et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression. Am J Psychiatry. 2015;172(3):227-236. PubMed PMID 25585035
5. Glynne S, et al. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women. Arch Womens Ment Health. 2024. PubMed PMID 38480538
6. FDA. FDA Approves Brexanolone for Postpartum Depression. March 2019. fda.gov
7. Gleason CE, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the KEEPS-Cognitive and Affective Study. PLoS Med. 2015;12(6):e1001833. PubMed PMID 26035291
8. He J, et al. Global, regional, and national burden of anxiety disorders during perimenopause (1990-2021) and projections to 2035. PMC. 2024. PMC11706191